Linagliptin as Add on to Basal Insulin in the Elderly

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT02240680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02240680
  • EudraCT 2014-000904-88
Other papers using this trial's data
  • Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial Advances in therapy, 2019-10 DOI, PubMed 31482511, PMC6822821 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Colombia, Denmark, Finland, Germany, Greece, Ireland, Japan, Mexico, New Zealand, Poland, Romania, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02240680. Randomized; double masking; primary purpose treatment. Start 2014-09-23 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin as Add on to Basal Insulin in the Elderly
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
placebo
Intervention (Drug)
linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02240680
Content hash
cf32ce841babeafa6d7864a5ce3918a5811afddbd456c3bc5c62b1d719db3ffd